A parent, desperate for reliable guidance on autism treatments for their child, turns to what should be the most trustworthy source in the nation—the Food and Drug Administration's website—only to find that a page once dedicated to warning against fraudulent and dangerous "cures" has
In the high-stakes world of pharmaceuticals, where the success of blockbuster drugs can define a company's trajectory for a decade, Eli Lilly is making a calculated and aggressive pivot to secure its future beyond the unprecedented success of its cardiometabolic medicines Zepbound and
A staggering 58% of new pharmaceutical launches fail to meet market expectations, a statistic that points not to a string of bad luck but to a systemic crisis brewing within the industry. Many companies find themselves trapped in a "Gambler's Fallacy," repeatedly deploying outdated
A significant advancement in psychiatric medicine has emerged from the clinical pipeline, as a novel psilocybin-based compound demonstrated conclusive success in a pivotal late-stage trial for treatment-resistant depression. This development signals a potential paradigm shift, moving
A New Contender Enters the Ring for Vision Treatment For millions living with the wet form of age-related macular degeneration (wet AMD), the prospect of frequent, invasive eye injections is a burdensome reality. The landscape of treatment has long been dominated by effective but demanding
A Surprising Setback: FDA's Unexpected Rejection Jolts Disc Medicine and Patient Community In a significant blow to Disc Medicine and the patient community it serves, the U.S. Food and Drug Administration (FDA) has officially rejected the company's application for bitopertin, a novel drug
